🟠 Moderate Evidence
A standard B12 blood test may show “normal” levels in patients who are nonetheless functionally deficient in the vitamin at the cellular level. The discrepancy arises because routine tests measure total B12 in circulation, which includes both biologically active and inactive forms — a distinction most clinicians do not explore in standard practice.
Key takeaways
- Approximately 70–80% of circulating B12 is bound to haptocorrin and is cleared by the liver without reaching cells that require it
- Only 20–30% of B12 is bound to transcobalamin, the protein that actually delivers the vitamin to cells for functional use
- Standard B12 tests measure total B12 (both active and inactive forms), potentially masking functional deficiency in individual patients
- The active form, holoTC (holotranscobalamin), can be measured separately but is rarely ordered due to cost and insurance coverage limitations
The hidden problem with standard B12 testing
When a patient receives a routine B12 test, the laboratory reports a single number representing total serum B12 concentration. However, this measurement conflates two fundamentally different pools of the vitamin circulating in blood. According to biochemical literature on B12 transport, approximately 70–80% of B12 in circulation binds to haptocorrin, a carrier protein that delivers the vitamin to the liver for metabolism and excretion — a pathway that does not supply B12 to peripheral tissues requiring it for metabolic function.
The remaining 20–30% binds to transcobalamin (also called TC II), the physiologically active carrier protein that docks with cell receptors and transfers B12 into cells for actual enzymatic work. A patient with a total B12 level in the “normal” reference range may have a disproportionately high fraction bound to haptocorrin, meaning functionally available B12 at the cellular level is substantially lower than the total number suggests.
Why two patients with identical B12 levels may have opposite clinical outcomes
The B12 transport problem: inactive vs. active circulation
Approximate distribution of B12 carriers and metabolic fate in circulation
Source: B12 biochemistry literature | Georgian Medical Journal News
Two individuals with identical total serum B12 results (for example, both at 450 pg/mL, within normal range) can have markedly different proportional distributions of B12 between haptocorrin and transcobalamin. One patient might have 350 pg/mL bound to haptocorrin and only 100 pg/mL as the active TC form, while another has 200 pg/mL haptocorrin-bound and 250 pg/mL TC-bound. Both report the same total, but the second patient has 2.5 times more functional B12 reaching cells.
The specific measurement of active B12, called holotranscobalamin (holoTC), directly quantifies the fraction available for cellular uptake. However, most clinical laboratories do not routinely order this test because it costs more than total B12 testing and most insurance formularies default to the cheaper, less discriminating total B12 assay, according to clinical practice patterns in B12 assessment.
B12’s dual metabolic roles inside the cell
Once B12 crosses the cell membrane via transcobalamin receptors, the vitamin undergoes enzymatic conversion into one of two active coenzyme forms, each serving distinct metabolic pathways. In the cytoplasm, B12 becomes methylcobalamin, which powers methionine synthase — an enzyme that generates methyl groups essential for DNA synthesis, neurotransmitter production (including serotonin and dopamine), and maintenance of myelin sheaths insulating nerve fibers.
Inside mitochondria, B12 becomes adenosylcobalamin, which activates methylmalonyl-CoA mutase — an enzyme required for processing certain fatty acids and branched-chain amino acids into usable cellular fuel. Functional B12 deficiency can impair either pathway selectively, depending on which tissues are most metabolically active and which have the greatest demand for B12 transport. A patient with normal total B12 but low holoTC may have sufficient B12 for cytoplasmic reactions but insufficient for mitochondrial energy metabolism, or vice versa.
Approximately 70–80% of circulating B12 is bound to haptocorrin and directed toward hepatic clearance, leaving only 20–30% available through the transcobalamin carrier for actual cellular delivery and metabolic use.
— B12 transport and metabolism literature
What this means
Frequently asked questions
What symptoms might indicate functional B12 deficiency despite a normal total B12 test?
Functional B12 deficiency can present as fatigue, peripheral neuropathy (tingling or numbness in hands and feet), cognitive difficulties, memory problems, mood disturbances, or megaloblastic anaemia. These symptoms arise when insufficient B12 reaches cells to support methylation reactions (DNA synthesis, neurotransmitter production) or mitochondrial energy metabolism. If you have these symptoms with a normal total B12, ask your clinician about holoTC testing.
Who is at highest risk for functional B12 deficiency?
Risk groups include strict vegetarians and vegans (B12 is primarily found in animal products), patients with pernicious anaemia or atrophic gastritis (which impairs B12 absorption), those with Crohn’s disease or coeliac disease affecting the terminal ileum, and patients taking metformin or proton-pump inhibitors long-term. Older adults also have reduced stomach acid, which is needed to release B12 from food. These groups may benefit from holoTC testing even with normal total B12 results.
Is holoTC testing widely available?
HoloTC measurement is available through specialist laboratories but is not routinely ordered by most primary care clinicians because it costs more than total B12 testing and is not covered by all insurance plans. Advocacy for broader coverage and insurance reimbursement could improve access. Request holoTC testing from your healthcare provider if you have symptoms suggestive of B12 deficiency; if insurance initially denies it, clinical documentation of B12-deficiency symptoms may support coverage appeals.
As clinical understanding of B12 biochemistry advances, the limitations of total B12 testing become increasingly apparent. Integrating holoTC measurement into diagnostic algorithms for suspected B12 deficiency could improve diagnostic precision and enable earlier intervention in patients with functional B12 insufficiency masked by normal total B12 results. Further research examining the clinical utility and cost-effectiveness of holoTC screening in high-risk populations may reshape B12 testing standards in primary care and specialist practice.
Source: B12 transport and biochemistry literature
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
